SAKAR · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 51/100 — Quality 66 · Valuation 1 · Momentum 100
| Share price | ₹898.80 |
| Market cap | ₹1,810 Cr |
| P/E ratio | 60.2 |
| P/B ratio | 5.6 |
| ROE | 137.0% |
| ROCE | 12.8% |
| Book value | ₹145.98 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹252 Cr | ₹30 Cr | 27.0% |
| 2025 | ₹178 Cr | ₹18 Cr | 28.0% |
| 2024 | ₹153 Cr | ₹12 Cr | 25.0% |
| 2023 | ₹133 Cr | ₹13 Cr | 25.0% |
| 2022 | ₹128 Cr | ₹15 Cr | 23.0% |
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-infl